105 related articles for article (PubMed ID: 16353248)
21. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
22. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
23. Cellular expression, localization and interactions of the product of the human MOST-1 gene associated with breast and prostate cancers.
Tan JM; Chow VT
Int J Oncol; 2007 Jan; 30(1):81-9. PubMed ID: 17143515
[TBL] [Abstract][Full Text] [Related]
24. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines.
Chow L; Rezmann L; Imamura K; Wang L; Catt K; Tikellis C; Louis WJ; Frauman AG; Louis SN
Prostate; 2008 May; 68(6):651-60. PubMed ID: 18288685
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
26. Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells.
Ni J; Pang ST; Yeh S
Prostate; 2007 Apr; 67(5):463-71. PubMed ID: 17252538
[TBL] [Abstract][Full Text] [Related]
27. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
28. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
29. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer.
Konishi N; Shimada K; Nakamura M; Ishida E; Ota I; Tanaka N; Fujimoto K
Clin Cancer Res; 2008 Jul; 14(14):4408-16. PubMed ID: 18628455
[TBL] [Abstract][Full Text] [Related]
30. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
Wu C; Zhang L; Bourne PA; Reeder JE; di Sant'Agnese PA; Yao JL; Na Y; Huang J
Prostate; 2006 Aug; 66(11):1125-35. PubMed ID: 16652382
[TBL] [Abstract][Full Text] [Related]
31. Aberrant prothymosin-alpha expression in human bladder cancer.
Tsai YS; Jou YC; Lee GF; Chen YC; Shiau AL; Tsai HT; Wu CL; Tzai TS
Urology; 2009 Jan; 73(1):188-92. PubMed ID: 18692879
[TBL] [Abstract][Full Text] [Related]
32. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel genes expressed during rhabdomyosarcoma differentiation using cDNA microarrays.
Carey KA; Segal D; Klein R; Sanigorski A; Walder K; Collier GR; Cameron-Smith D
Pathol Int; 2006 May; 56(5):246-55. PubMed ID: 16669873
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
35. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
[TBL] [Abstract][Full Text] [Related]
36. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
[TBL] [Abstract][Full Text] [Related]
37. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
38. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
[TBL] [Abstract][Full Text] [Related]
39. PrLZ expression is associated with the progression of prostate cancer LNCaP cells.
Li L; Zhang D; Zhang L; Zhu G; Sun Y; Wu K; Wang X; He D
Mol Carcinog; 2009 May; 48(5):432-40. PubMed ID: 18800346
[TBL] [Abstract][Full Text] [Related]
40. MCM7 amplification and overexpression are associated with prostate cancer progression.
Ren B; Yu G; Tseng GC; Cieply K; Gavel T; Nelson J; Michalopoulos G; Yu YP; Luo JH
Oncogene; 2006 Feb; 25(7):1090-8. PubMed ID: 16247466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
